New hope for stomach cancer patients Who've tried everything?

NCT ID NCT07096609

Recruiting now Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug lenvatinib in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to three standard treatments. Participants take lenvatinib capsules daily, and researchers will measure how many patients have their disease controlled (shrink or stay stable) after 12 weeks. The goal is to see if lenvatinib can provide a new option when other drugs no longer work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenvatinib (a targeted cancer drug taken as a daily capsule)
What this could lead to: If successful, lenvatinib could offer a new treatment option for people with advanced GIST who have run out of standard therapies.
What could go wrong: This is an early phase 2 study with only 48 participants, so results may not apply broadly. Lenvatinib can cause side effects like high blood pressure, fatigue, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIST

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.